AVROBIO, Inc. (AVRO): Price and Financial Metrics


AVROBIO, Inc. (AVRO)

Today's Latest Price: $21.70 USD

0.13 (0.60%)

Updated Jun 4 2:00pm

Add AVRO to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 336 in Biotech

See all "A" rated Strong Buy stocks

AVRO Daily Price Range
AVRO 52-Week Price Range

AVRO Stock Price Chart More Charts


AVRO Price/Volume Stats

Current price $21.70 52-week high $29.32
Prev. close $21.57 52-week low $9.76
Day low $21.20 Volume 231,402
Day high $22.31 Avg. volume 336,523
50-day MA $15.63 Dividend yield N/A
200-day MA $17.47 Market Cap 781.96M

AVROBIO, Inc. (AVRO) Company Bio


AVROBIO, Inc., a clinical stage gene therapy company, focuses on developing potentially curative ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose. It lead product candidate in AVR-RD-01, which is in Phase 1 clinical trial for the treatment of Fabry disease. The company is also developing AVR-RD-02 for the treatment of Gaucher disease; AVR-RD-03 for the treatment of Pompe disease; and AVR-RD-04 for the treatment of cystinosis. The company was founded in 2015 and is based in Cambridge, Massachusetts.


AVRO Latest News Stream


Event/TimeNews Detail
Loading, please wait...

AVRO Latest Social Stream


Loading social stream, please wait...

View Full AVRO Social Stream

Latest AVRO News From Around the Web

Below are the latest news stories about AVROBIO Inc that investors may wish to consider to help them evaluate AVRO as an investment opportunity.

AVROBIO Presents New Preclinical Data on Lentiviral Gene Therapy Program for Pompe Disease at ASGCT 2020

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AVRO--AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced new preclinical data for AVR-RD-03 for Pompe disease showcasing how its lentiviral gene therapy approach may potentially correct Pompe disease manifestations in the muscle and central nervous system (CNS). The data will be presented today at the American Society of Gene & Cell Therapy (ASGCT) 23rd Ann

Business Wire | May 14, 2020

AVROBIO Reports Updated Clinical Data from Investigational Gene Therapy Programs for Fabry Disease and Cystinosis

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AVRO--AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced new clinical data from its investigational programs for Fabry disease and cystinosis. The data will be presented today at the American Society of Gene & Cell Therapy (ASGCT) 23rd Annual Meeting. “We’re excited to see continued strong results across our clinical programs for Fabry disease and cystinosi

Business Wire | May 13, 2020

We're Not Very Worried About AVROBIO's (NASDAQ:AVRO) Cash Burn Rate

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Yahoo | May 9, 2020

Why Earnings Season Could Be Great for AVROBIO (AVRO)

AVROBIO (AVRO) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Zacks Investment Research | May 8, 2020

AVROBIO Reports 1Q 2020 Financial Results and Provides Business Update

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AVRO--AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today reported financial results for the quarter ended March 31, 2020 and provided a business update. “Our strong progress has continued, as evidenced by recently announced collaborations with Saladax Biomedical, Inc. and Magenta Therapeutics, which highlight our commitment to leading innovation in the lentiviral gene th

Business Wire | May 7, 2020

Read More 'AVRO' Stories Here

AVRO Price Returns

1-mo 38.13%
3-mo 6.27%
6-mo 20.69%
1-year 51.32%
3-year N/A
5-year N/A
YTD 7.80%
2019 20.90%
2018 N/A
2017 N/A
2016 N/A
2015 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.6612 seconds.